Parameters evaluated
- Whole-body glucose utilization rate (TO)
- Hepatic glucose production (HGP)
- Glucose infusion rate (GIR)
- Whole-body glycolysis rate.
- Whole-body glycogen synthesis rate
Gold-standard method for assessing drug compound efficacy on whole-body INSULIN SENSITIVITY.
The hyperinsulinemic euglycemic clamp using RADIOACTIVE LABELED TRACERS is a unique solution for distinguishing your compound from your competitors' products.
Key benefits
- Sensitivity (15%) sufficient to detect a statistically significant impact of your compound on insulin resistance.
- Essential and robust data for your records: the isotopic glucose enrichment procedure is a unique solution giving access to hepatic glucose production, glycolysis and glycogen synthesis.
- Specific mechanisms targeted by your compound: the insulin dose is chosen to prioritize either hepatic glucose production or peripheral glucose utilization.
Species
- Rat
- Mouse
Clamp options
Two-step euglycemic hyperinsulinemic clamp:
- Provides a global picture of hepatic and peripheral insulin resistance in a single animal: offers an integrated evaluation of mechanisms which are not animal-dependent, saving animals, time, and money.
Hyperglycemic hyperinsulinemic clamp:
- Provides unique whole body data on insulin-regulated hepatic glycogen synthesis: this technique places the focus on hepatic glycogen synthesis, which is strongly stimulated in hyperglycemic conditions.
Two-step euglycemic hyperinsulinemic clamp + 3H-glucose
Hyperglycemic hyperinsulinemic clamp + 3H-glucose
Add-on studies
- Individual tissue glucose uptake assay for identifying specific tissues targeted by your compound, thereby identifying unexpected adverse effects and additional benefits, or for stratifying heterogeneous patient populations for clinical trials.
- FFA turnover technique to complete the overview of your drug compound's impact on whole-body INSULIN SENSITIVITY and lipid metabolism.
Scientific publications
- Fyfe MC et al, Diabetologia 50:1277-87, 2007
- Andreelli F et al, Endocrinology 147: 2432-41, 2006
- Knauf C et al, J Clin Invest 115: 3554-63, 2005
- Cook S et al, Diabetes 53:2067-72, 2004
- Burcelin R et al, Diabetes 50: 1282-9, 2001
